Hemangioma is the birthmark or benign tumors of infancy that occurs due to an abnormal collection of blood vessels. This occurs in 5-10% of infants worldwide. Increasing cases of hemangioma, increasing use of technology, and different treatment options are key drivers for the global Hemangioma market. Increasing knowledge about the disorder and treatment, introduction of new drugs and therapies, and rapidly changing medical technology are major driving forces of the global hemangioma market. Increasing investment in R&D to develop more advanced product for the market is another major factor for the market.
The Global Hemangioma market is growing at the CAGR of ~3.2% during the forecast period and expected to reach US$ 294.8 million by 2023.
Key Players for Global Hemangioma Market:
Some of the key players in this market are: Akrimax Pharmaceuticals, LLC. (US), AstraZeneca (UK), Cutting Edge Laser Technologies (US), Linline Medical Systems (France), Novartis AG (Switzerland), Pfizer Inc. (US), Pierre Fabre (US) Quanta System S.p.A. (Italy), and others.
Segments:
Global Hemangioma Market has been segmented on the basis of type which Capillary hemangioma, Cavernous hemangioma (Cerebral cavernous malformations, Liver cavernous hemangioma, Eye cavernous hemangioma), Compound hemangioma, Lobular capillary hemangioma (pyogenic granuloma), and others. Cavernous hemangioma is further sub-segmented into cerebral cavernous malformations, liver cavernous hemangioma, and Eye cavernous hemangioma.
On the basis of diagnosis, it is segmented into Ultrasound, MRI, CT scan, and others.
On the basis of treatment, the market is segmented into medical therapy, laser therapy, surgery, and others. Medical therapy is further sub-segmented into systemic, intralesional and topical. Laser therapy is sub-segmented into Flash lamp pulsed dye laser, intralesional laser, carbon dioxide laser.
Request Customization
Get a Sample
Get a Sample
Request Customization